Multi-country

Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority

Lenacapavir Turns HIV Prevention Into an Access Stress Test

Physical activity continues to strengthen its case as a cross-disease prevention strategy

Can cortisol become the next target in type 2 diabetes?

An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer

Hepatitis B Functional Cure Moves Closer, But Access Still Starts With Diagnosis

Huntington’s Disease Gets an Oral Target-Engagement Signal
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
